The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Open accessAbstract
Key Points: Engineered T-cell receptors can have redundant recognition of alternative protein motifs, resulting in severe cardiac toxicity. The use of induced pleuripotent stem cells (iPSCs) is a promising approach to identify potential off-target effects of engineered T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Truncations of titin causing dilated cardiomyopathy
Herman, D. S., Lam, L., Taylor, M. R. G., Wang, L., Teekakirikul, P., Christodoulou, D., Conner, L., DePalma, S. R., McDonough, B., Sparks, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110186 · Cited by 1,485
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288
Cited by
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Self-citationTargeting cardiac fibrosis with engineered T cells
Aghajanian, H., Kimura, T., Rurik, J. G., Hancock, A. S., Leibowitz, M. S., Li, L., Scholler, J., Monslow, J., Lo, A., Han, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1546-z · Cited by 801
Self-citationAdverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Immune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319
The MAGE protein family and cancer
Weon, J. L., & Potts, P. R. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.08.002 · Cited by 257
Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002071 · Cited by 250
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases
Lee, A. K., & Potts, P. R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.005 · Cited by 136
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
Roybal, K. T., & Lim, W. A. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052302 · Cited by 124
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
Lu, D., Chen, Y., Jiang, M., Wang, J., Li, Y., Ma, K., Sun, W., Zheng, X., Qi, J., Jin, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42010-1 · Cited by 101
Adoptive T-cell therapy for cancer: the era of engineered T cells
Bonini, C., & Mondino, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545552 · Cited by 93
De novo-designed pMHC binders facilitate T cell–mediated cytotoxicity toward cancer cells
Johansen, K. H., Wolff, D. S., Scapolo, B., Fernández-Quintero, M. L., Risager Christensen, C., Loeffler, J. R., Rivera-de-Torre, E., Overath, M. D., Kjærgaard Munk, K., Morell, O., et al. (2025) · Science · doi:10.1126/science.adv0422 · Cited by 77
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100304 · Cited by 62
Brown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59
Is cancer gene therapy an empty suit?
Brenner, M. K., Gottschalk, S., Leen, A. M., & Vera, J. F. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70173-6 · Cited by 52
Breaking Bottlenecks for the TCR Therapy of Cancer
Gaissmaier, L., Elshiaty, M., & Christopoulos, P. (2020) · Cells · doi:10.3390/cells9092095 · Cited by 52
TCR catch bonds nonlinearly control CD8 cooperation to shape T cell specificity
Qin, R., Zhang, Y., Shi, J., Wu, P., An, C., Li, Z., Liu, N., Wan, Z., Hua, T., Li, X., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01077-9 · Cited by 35
Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy
Vigneron, N., Abi Habib, J., & Van den Eynde, B. J. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.07.007 · Cited by 33
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer
Jin, Y., Lorvik, K. B., Jin, Y., Beck, C., Sike, A., Persiconi, I., Kvaløy, E., Saatcioglu, F., Dunn, C., & Kyte, J. A. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2022.06.007 · Cited by 26
Phage display enables machine learning discovery of cancer antigen–specific TCRs
Croce, G., Lani, R., Tardivon, D., Bobisse, S., de Tiani, M., Bragina, M., Perez, M. A. S., Michaux, J., Pak, H. S., Michel, A., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads5589 · Cited by 23
Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors
Lo Presti, V., Buitenwerf, F., van Til, N. P., & Nierkens, S. (2020) · Vaccines · doi:10.3390/vaccines8040733 · Cited by 14
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain
Meeuwsen, M. H., Wouters, A. K., Wachsmann, T. L. A., Hagedoorn, R. S., Kester, M. G. D., Remst, D. F. G., van der Steen, D. M., de Ru, A. H., van Hees, E. P., Kremer, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01408-6 · Cited by 12
Metadata
- Authors
- Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., Binder-Scholl, G. K., Smethurst, D. P., Gerry, A. B., Pumphrey, N. J., Bennett, A. D., Brewer, J. E., Dukes, J., Harper, J., Tayton-Martin, H. K., Jakobsen, B. K., Hassan, N. J., Kalos, M., & June, C. H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-08-08
- Volume
- 122
- Issue
- 6
- Pages
- 863-871
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2020312840
- Cited by
- 1,179
- References
- 7
- FWCI
- 42.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
